OBJECTIVE: This study aimed to evaluate the trends in the incidence, survival, and surgical therapy for Canadian patients affected by pancreatic cancer (PC). METHODS: The incidence, mortality, number of resections, and outcomes of patients with PC stratified by year, sex, and province were extracted from Canadian cancer databases. RESULTS: In 2012, PC was diagnosed in 4600 Canadians and it was responsible for 4300 deaths. The age-standardized incidence was 9 to 10 new cases per 100,000 individuals. The mortality rate remained the highest among all the solid tumors with a case-to-fatality ratio of 0.93. The age-standardized 5-year relative survival was 9.1% (95% confidence interval [CI], 8.3-10). There were geographic variations among provinces with the highest survival registered in Ontario (10.9%; 95% CI, 9.9-12) and the lowest survival reported in Nova Scotia (4.7%; 95% CI, 2.8-7.2). The percentage of patients who underwent surgery decreased from 19% (2006-2007) to 17% (2009-2010). Pancreatic resections were performed in high-volume centers in 74% of cases. In-hospital mortality was 5%, 93% of patients were discharged home, and 36% of patients required home support after discharge. CONCLUSIONS: Long-term outcomes of Canadian patients affected by PC remain unsatisfactory, with only 9% of the patients surviving at 5 years. Surgical therapy was performed only in 17% to 19% of patients.
OBJECTIVE: This study aimed to evaluate the trends in the incidence, survival, and surgical therapy for Canadian patients affected by pancreatic cancer (PC). METHODS: The incidence, mortality, number of resections, and outcomes of patients with PC stratified by year, sex, and province were extracted from Canadian cancer databases. RESULTS: In 2012, PC was diagnosed in 4600 Canadians and it was responsible for 4300 deaths. The age-standardized incidence was 9 to 10 new cases per 100,000 individuals. The mortality rate remained the highest among all the solid tumors with a case-to-fatality ratio of 0.93. The age-standardized 5-year relative survival was 9.1% (95% confidence interval [CI], 8.3-10). There were geographic variations among provinces with the highest survival registered in Ontario (10.9%; 95% CI, 9.9-12) and the lowest survival reported in Nova Scotia (4.7%; 95% CI, 2.8-7.2). The percentage of patients who underwent surgery decreased from 19% (2006-2007) to 17% (2009-2010). Pancreatic resections were performed in high-volume centers in 74% of cases. In-hospital mortality was 5%, 93% of patients were discharged home, and 36% of patients required home support after discharge. CONCLUSIONS: Long-term outcomes of Canadian patients affected by PC remain unsatisfactory, with only 9% of the patients surviving at 5 years. Surgical therapy was performed only in 17% to 19% of patients.
Authors: A L Smith; C Bascuñana; A Hall; A Salman; A Z Andrei; A Volenik; H Rothenmund; D Ferland; D Lamoussenery; A S Kamath; R Amre; D Caglar; Z H Gao; D G Haegert; Y Kanber; R P Michel; G Omeroglu-Altinel; J Asselah; N Bouganim; P Kavan; G Arena; J Barkun; P Chaudhury; S Gallinger; W D Foulkes; A Omeroglu; P Metrakos; G Zogopoulos Journal: Curr Oncol Date: 2015-04 Impact factor: 3.677
Authors: R S Raju; N Coburn; N Liu; J M Porter; S J Seung; M C Cheung; N Goyert; N B Leighl; J S Hoch; M E Trudeau; W K Evans; K N Dainty; C C Earle; N Mittmann Journal: Curr Oncol Date: 2015-12 Impact factor: 3.677
Authors: Mustapha Tehfe; Scot Dowden; Hagen Kennecke; Robert El-Maraghi; Bernard Lesperance; Felix Couture; Richard Letourneau; Helen Liu; Alfredo Romano Journal: Adv Ther Date: 2016-04-16 Impact factor: 3.845
Authors: Michelle J Schmahl; Daniel P Regan; Adam C Rivers; William C Joesten; Michael A Kennedy Journal: PLoS One Date: 2018-07-17 Impact factor: 3.240
Authors: Stephen F Hall; Colleen Webber; Patti A Groome; Christopher M Booth; Paul Nguyen; Yvonne DeWit Journal: Cancer Med Date: 2019-01-04 Impact factor: 4.452
Authors: Jaspreet Sandhu; Vanessa De Rubeis; Michelle Cotterchio; Brendan T Smith; Lauren E Griffith; Darren R Brenner; Ayelet Borgida; Steven Gallinger; Sean Cleary; Laura N Anderson Journal: BMC Cancer Date: 2020-02-21 Impact factor: 4.430